Search - tctmd.com

Displaying 1 - 20 of 21

Sort: Relevancy | Date

News Daily News

Nearly 150 Million US Adults Eligible for CKM Syndrome Meds

Caitlin E. Cox

February 02, 2026

News Daily News

SURPASS-CVOT Published: Large Trial Confirms CVD Efficacy of Tirzepatide

Michael O'Riordan

December 18, 2025

News Daily News

AI-Supported Coaching Shows Promise for Improving Glycemic Control

L.A. McKeown

August 25, 2025

News Daily News

Glipizide, Commonly Used Sulfonylurea, Linked to Greater CV Risks

Michael O'Riordan

August 01, 2025

News Daily News

Medicaid Patients With Type 2 Diabetes Face Hurdles Getting Cardioprotective Meds

Michael O'Riordan

April 25, 2025

News Opinion CV Team Dispatch

January 2025 Dispatch for the CV Team

L.A. McKeown

January 24, 2025

News Opinion CV Team Dispatch

December 2024 Dispatch for the CV Team

L.A. McKeown

December 20, 2024

SUMMIT: Tirzepatide ‘Huge Win’ for HFpEF Patients With Obesity

News Conference News AHA 2024

SUMMIT: Tirzepatide a ‘Huge Win’ for HFpEF Patients With Obesity

Michael O'Riordan

November 16, 2024

News Daily News

SOUL: Oral Semaglutide Cuts CV Events in Diabetic Patients

L.A. McKeown

October 23, 2024

News Conference News EACTS 2024

Will Semaglutide Change Cardiac Surgery? It Already Has

Yael L. Maxwell

October 10, 2024

News Daily News

No Uptick in Suicidal Thinking With GLP-1 Drugs: Medicare Data

Yael L. Maxwell

July 15, 2024

News Opinion Editor's Corner

TCTMD’s Top 10 Most Popular Stories for May 2024

Shelley Wood

May 31, 2024

News Conference News HFSA 2023

Semaglutide Works Across LVEF Range: STEP-HFpEF Analysis

Todd Neale

October 11, 2023

News Daily News

Diabetes in Middle Age Linked to Earlier CVD Risk: Danish Study

L.A. McKeown

October 10, 2023

News Conference News ESC 2023

STEP-HFpEF: Semaglutide Cuts Weight and Symptoms, Boosts Function

Shelley Wood

August 25, 2023

News Daily News

New Chronic Heart Disease Guidelines Update Roles of GDMT, Imaging, and Revascularization

Michael O'Riordan

July 20, 2023

News Features

Skyrocketing Popularity Puts GLP-1 Agonists for Weight Loss on Cardiology’s Radar

L.A. McKeown

May 12, 2023

News Daily News

New Expert Consensus Papers Aim to Boost Management, Outcomes in HFpEF

L.A. McKeown

April 19, 2023

News Conference News ACC 2023

Diabetic Patients in Middle East, Africa Overburdened by ASCVD

Michael O'Riordan

March 14, 2023

News Opinion Editor's Corner AHA 2021

AHA 2021 Tackles AF Triggers, Watchful Waiting in AS, Data Overload, and More

Shelley Wood

November 08, 2021

Advertisement

Nearly 150 Million US Adults Eligible for CKM Syndrome Meds

SURPASS-CVOT Published: Large Trial Confirms CVD Efficacy of Tirzepatide

AI-Supported Coaching Shows Promise for Improving Glycemic Control

Glipizide, Commonly Used Sulfonylurea, Linked to Greater CV Risks

Medicaid Patients With Type 2 Diabetes Face Hurdles Getting Cardioprotective Meds

January 2025 Dispatch for the CV Team

December 2024 Dispatch for the CV Team

SUMMIT: Tirzepatide a ‘Huge Win’ for HFpEF Patients With Obesity

SOUL: Oral Semaglutide Cuts CV Events in Diabetic Patients

Will Semaglutide Change Cardiac Surgery? It Already Has

No Uptick in Suicidal Thinking With GLP-1 Drugs: Medicare Data

TCTMD’s Top 10 Most Popular Stories for May 2024

Semaglutide Works Across LVEF Range: STEP-HFpEF Analysis

Diabetes in Middle Age Linked to Earlier CVD Risk: Danish Study

STEP-HFpEF: Semaglutide Cuts Weight and Symptoms, Boosts Function

New Chronic Heart Disease Guidelines Update Roles of GDMT, Imaging, and Revascularization

Skyrocketing Popularity Puts GLP-1 Agonists for Weight Loss on Cardiology’s Radar

New Expert Consensus Papers Aim to Boost Management, Outcomes in HFpEF

Diabetic Patients in Middle East, Africa Overburdened by ASCVD

AHA 2021 Tackles AF Triggers, Watchful Waiting in AS, Data Overload, and More

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content